There may be a way to detect multiple myeloma (MM) earlier — effectively shortening the longer diagnostic interval that is typically associated with...
News
Expert Reflects on “Incredible” Data Seen With bb2121 in Heavily Pretreated Myeloma
The deep and durable phase I responses seen with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with...
Two CAR T-Cell Therapies Greenlighted in Europe
The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric...
An Integrative Multiomics Approach to Multiple Myeloma
When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However,...
Research Review: Multiple Myeloma – Issue 27
Issue 27 of Multiple Myeloma Research Review Highlights include: Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of...
CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsena
CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several...
PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma
Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing...
Once-Weekly Carfilzomib Submitted for FDA Approval in Myeloma
FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for...
Immune Approaches Hold Great Promise in Myeloma, Expert Says
Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has...
Patient/Caregiver Survey
Please take 10 minutes to complete this survey to help us put myeloma on New Zealand’s health agenda and help you to have the best lives possible....
Pediatric Guidelines for CAR T-Cell Therapy Help Nurses Recognize AEs Earlier
A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic...
Elotuzumab Triplet Granted Priority Review by FDA for Myeloma
A supplemental biologics license application (sBLA) for elotuzumab (Empliciti) has been granted a priority review by the FDA for use in combination...